From these results, the optimum acrylic monomer content was found to be about click here 30 wt %, which realized reasonably advantages of both poly(urethane-urea) and acrylic polymer. (c) 2011 Wiley Periodicals, Inc. J Appl Polym Sci, 2011″
“Study
Design. A case report of polyostotic fibrous dysplasia including thoracic spine, sacral vertebrae, and temporal bone, with the symptom of back pain.
Objective. To treat the lesions with percutaneous kyphoplasty.
Summary of Background Data. Polyostotic fibrous dysplasia involving either spine or temporal bone is rarely seen. Few reports of this disorder appear in the literature. This is the first case including thoracic spine, sacrum, and temporal bone together presented to date.
Methods. The patient was a 56-year-old woman with polyostotic fibrous dysplasia involving the thoracic spine of the eighth, ninth, and 10th vertebral body; adjacent rib; the right temporal bone and the sacrum. Percutaneous kyphoplasty in ninth and 10th vertebral body was carried out to achieve substantial pain relief and rapid stabilization of the spine with minimal invasion.
Results. The patient experienced complete pain relief and had no clinical complications associated with the cement leakage. The patient tolerated the procedure well. There were no clinical complications and substantial
pain relief was noted within hours of the procedure. NSC 617989 HCl She has no pain or disability at 1-year follow-up.
Conclusion. Percutaneous kyphoplasty was a good therapeutic option for the reported patient.”
“Background: Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated vaccine effectiveness (VE) against severe rotavirus gastroenteritis (RVGE) hospitalizations.
Methods: Matched case-control
study conducted at 4 hospitals in Belem from May 2008 to May 2009. Cases were children selleck chemical hospitalized with RVGE age-eligible to have received 2 doses of the human RV vaccine (>= 12 weeks of age and born after March 6, 2006). For each case, 1 neighborhood and 1 hospital control without gastroenteritis was selected, matching by birth date (+/- 8 and +/- 6 weeks, respectively). Matched odds ratio of 2-dose RV vaccination in cases versus controls was used to estimate VE (1 – odds ratio x 100%).
Results: Of 538 RVGE cases, 507 hospital controls and 346 neighborhood controls included, 54%, 61%, and 74% had received both RV vaccine doses. VE against RVGE hospitalization was 75.8% (95% confidence interval [CI]: 58.1-86.0) using neighborhood controls and 40.0% (95% CI: 14.2-58.1) using hospital controls. VE in children 3 to 11 months and >= 12 months of age was 95.7% (95% CI: 67.8-99.4) and 65.1% (95% CI: 37.2-80.6) using neighborhood controls, and 55.6% (95% CI: 12.3-77.5) and 32.1% (95% CI: -3.7-55.5) using hospital controls. G2P[4] accounted for 82.